| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327626 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
A large scale phase III randomized trial is now urgently needed to clarify the role of carboplatin-based IP chemotherapy in ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Keiichi Fujiwara, Maurie Markman, Mark Morgan, Robert L. Coleman,